The blockbuster immunomodulatory drug Revlimid (lenalidomide), which has become a backbone of many multiple myeloma treatment regimens and Bristol Myers Squibb Company’s top-selling drug, will face its first generics this year. Combined, generics for Revlimid and the chemotherapy drug Abraxane (nab-paclitaxel) will take about a $3bn bite out of the company’s 2022 revenue, according to new guidance from Bristol on 10 January, but current and future blockbusters are expected to fill that gap.
BMS Projects 2022 Growth Even With $3bn Hit From Revlimid, Abraxane Generics
Current Blockbusters, New Products To Make Up Difference
Bristol executives reiterated the company’s aggressive revenue growth expectations while outlining the impact Revlimid generics will have in Europe, Japan and – to a limited extent – in the US.
More from New Products
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.